Profile data is unavailable for this security.
About the company
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
- Revenue in USD (TTM)36.75bn
- Net income in USD7.71bn
- Incorporated1986
- Employees28.00k
- LocationAmgen IncOne Amgen Center DriveTHOUSAND OAKS 91320-1799United StatesUSA
- Phone+1 (805) 447-1000
- Fax+1 (302) 636-5454
- Websitehttps://www.amgen.com/
Mergers & acquisitions
| Acquired company | AMGN:NSQ since announced | Transaction value |
|---|---|---|
| Dark Blue Therapeutics Ltd | 15.11% | 840.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 48.19bn | 7.05bn | 123.70bn | 32.50k | 17.56 | 6.62 | 11.18 | 2.57 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Vertex Pharmaceuticals Inc | 12.00bn | 3.95bn | 124.83bn | 6.10k | 32.05 | 6.69 | 42.81 | 10.40 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | -- | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | -- | -- | 8.90 | 14.10 | 838.09 | 7.83 | -- | -- |
| Pfizer Inc | 62.58bn | 7.75bn | 156.81bn | 81.00k | 20.35 | -- | 11.26 | 2.51 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Gilead Sciences Inc | 29.44bn | 8.51bn | 192.28bn | 17.60k | 22.85 | 8.50 | 22.89 | 6.53 | 6.78 | 6.78 | 23.46 | 18.23 | 0.499 | 2.05 | 6.31 | -- | 14.42 | 8.03 | 18.05 | 9.82 | 78.84 | 78.01 | 28.91 | 18.13 | 1.31 | 36.91 | -- | 73.41 | 2.40 | 3.58 | 1,672.92 | 133.35 | -- | 3.04 |
| Amgen Inc | 36.75bn | 7.71bn | 198.80bn | 28.00k | 25.94 | 22.98 | 19.01 | 5.41 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 49.33m | 9.16% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 30.59m | 5.68% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 29.59m | 5.49% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 23.10m | 4.29% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 18.19m | 3.38% |
| Geode Capital Management LLCas of 31 Dec 2025 | 14.30m | 2.66% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 11.81m | 2.19% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 9.15m | 1.70% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 8.90m | 1.65% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 6.61m | 1.23% |
